Table 1.
Preoperative and operative characteristics of 721 patients with 2845 CRLMs preoperatively assessed by MRI (whole population) and 232 patients who did not receive preoperative chemotherapy.
| Characteristics | Whole population n = 721 | Patients without chemotherapy n = 232 |
|---|---|---|
| Age (years), median ± SD | 64 ± 10.8 | 66 ± 10.0 |
| Male, n (%) | 453 (62.2) | 149 (64.2) |
| BMI (kg/m2), median ± SD | 25 ± 3.34 | 27 ± 4.0 |
| Preoperative chemotherapy | 489 (67.8) | — |
| Number of cycles, median ± SD | 5 ± 6.5 | — |
| Oxaliplatin based, n (%) | 358 (49.7) | — |
| Irinotecan based, n (%) | 208 (28.8) | — |
| Biologics, n (%) | 309 (42.9) | — |
| Response to chemotherapy∗ | ||
| PR | 306 (62.6) | — |
| SD | 154 (31.5) | — |
| PD | 29 (5.9) | — |
| Preoperative radiologic workup | ||
| PET total body, n (%) | 317 (44) | 107 (46.1) |
| Number of LMs, median (range) | 2 (1–31) | 1 (1–4) |
| Maximum diameter (mm), median ± SD | 24 ± 22.05 | 19.4 ± 23.0 |
| Types of resection | ||
| (1) Minor hepatectomy, n(%) | 592 (82.1) | 194 (83.6) |
| (2) Laparoscopic resection, n(%) | 103 (14.3) | 62 (26.7) |
| (3) Redo-resection, n(%) | 50 (6.9) | 28 (18) |
BMI, body mass index; PR, partial response; SD, stable disease; PD, progression disease. ∗Rates calculated on 489 patients who received preoperative chemotherapy.